iVexSol provides a plasmid-free, stable lentiviral vector production platform that generates high-titer vectors on demand, significantly reducing wait times and costs associated with traditional manufacturing methods. This technology addresses the critical shortages in lentiviral vector supply, enabling faster clinical development and improved access to advanced therapies like CAR-T.
Funding
$39.2M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Traditional lentiviral vector production methods suffer from long lead times, high costs of goods, and frequent supply shortages, which can significantly delay clinical development and limit patient access to advanced therapies like CAR-T. These limitations stem from reliance on plasmid-based production, which is often inefficient and difficult to scale.
Solution
iVexSol offers a plasmid-free, stable lentiviral vector production platform designed to provide high-titer vectors on demand, addressing critical supply chain bottlenecks in cell and gene therapy. Their Intelligent Manufacturing™ platform utilizes stable producer cell lines to streamline vector production, reducing both time and costs compared to traditional methods. This next-generation process enables rapid and reliable production of high-quality, ready-to-use vectors at any scale, accelerating clinical development timelines and improving access to advanced therapies. iVexSol's platform includes vector fitness testing to ensure suitability, and the creation of a Master Cell Bank for long-term storage and on-demand vector production.
Target Audience
iVexSol primarily serves biopharmaceutical companies and research institutions involved in cell and gene therapy development, particularly those working on CAR-T and other advanced therapies requiring lentiviral vectors.
Features
- Plasmid-free lentiviral vector production eliminating the need for plasmid engineering and reducing manufacturing complexity
- Stable producer cell lines that provide a consistent and reliable source of lentiviral vectors
- Vector fitness testing to ensure the suitability of the vector for the intended application
- Generation of a clonally-derived Cell Bank of stable vector-producing cells for the production of the Gene of Interest
- Serum-free, suspension host cells engineered with microgram quantities of plasmid
- Cells are seeded, expanded, and screened to identify highly productive clones
- Optimal producers are further screened for stability, functionality, and safety
- Master Cell Bank (MCB) generation and long-term cryopreserved storage